Market LIVE
Published markets; coverage varies by country
Product profile · United States

Afrezza

 ·  Patent Litigation & Settlement History ↓

Ingredientinsulin human
Application typeBLA
Application022472
Product001
Dosage formPowder
RouteInhalation
Strength4UNITS/INH
Approval date2014-06-27
Marketing statusPrescription
Status event—
ApplicantMANNKIND
Product source

Current GenericRadar decision

Year2017
SelectionDEEP_REVIEW
ReviewFINAL
Anchor typeEXCLUSIVITY
Anchor date2017-06-27
Patent anchor—
Exclusivity anchor2017-06-27
Protection date—
First Final ANDA—
Status event—

BLA-05-02/11: Afrezza 4UNITS/INH; 2017 DEEP_REVIEW; anchor=2017-06-27 (EXCLUSIVITY). Flags: USER_DECISION_REQUIRED_NEW_OB_DP_U_CLAIMS_NOT_FULLY_REVIEWED; HISTORICAL_NDA_EXCLUSIVITY_CALCULATED_FROM_REVIEW_NOT_PUBLISHED_END_DATE; EXACT_FINAL_ANDA_NOT_SEPARATELY_RECHECKED;NO_DISQUALIFICATION_FROM_INDIRECT_BIOSIMILAR. Final operational judgment adopted; no verified=1 promotion. Update when evidence is found.

Patent estate

PatentEffective dateOfficial listingTRUE_DSDS gradeClaim classification / basisPTEPEDFamily
No patent facts are recorded for this product.

Regulatory exclusivity

CodeStart dateEnd dateScopeEntire productAll indicationsFull coverage dateCombinationSource
No exclusivity facts are recorded in this product snapshot.

2026-10-10 · PENDING_EXCLUSIVITY_CONFIRMATION · Historical coverage: NOT_COMPLETE

Generic approval evidence

Application / productEventFinal dateTentative dateApplicantAuthorized genericExact mappingSource
No generic approval facts are linked to this product.

Market Entry Information

API filings, authorized generics and linked regulatory milestones.

API Master Files & Certifications 0 records

Ingredient-level registrations from linked public manufacturer portfolios. A filing does not establish supply to this finished product. DMFs are not FDA approvals.

APIHolder / manufacturerHolder countryFiling typeNumberStatusFiled dateAvailable for referenceSourceLast verified
No master-file or certification records are linked through public manufacturer portfolios.

Authorized Generics 0 records

Authorized generics are shown separately from independent ANDA approvals.

Application / productApplicantEvent / status First marketed Product mappingSourceLast verified
No authorized-generic records are linked to this product.

Tentative ANDA Approvals 0 records

Tentative approval is not final approval. Historical tentative approvals remain visible after a linked final approval.

Application / productApplicantEvent / status Tentative date Follow-up final approvalProduct mappingSourceLast verified
No tentative-approval records are linked to this product.

Paragraph IV Challenges 0 records

Paragraph IV challenges below are sourced from legal records separately from FDA approvals. An ANDA filing, lawsuit or settlement does not establish final approval or commercial launch.

Application / productApplicantEvent / status Certification event date Product mappingSourceLast verified
No structured Paragraph IV certification events are linked in the available approval evidence.

Final ANDA Approvals 0 records

Approval dates do not establish commercial launch. Product mapping is shown for each linked record.

Application / productApplicantEvent / status Final approval date Product mappingSourceLast verified
No final-approval records are linked to this product.
Decision evidence (1)
TypeDateRoleBasisSource
BLA_PATENT_EXCLUSIVITY_REVIEW—BUSINESS_CLASSIFICATION_WITH_CONDITIONSBLA-05-02/11: Afrezza 4UNITS/INH; 2017 DEEP_REVIEW; anchor=2017-06-27 (EXCLUSIVITY). Flags: USER_DECISION_REQUIRED_NEW_OB_DP_U_CLAIMS_NOT_FULLY_REVIEWED; HISTORICAL_NDA_EXCLUSIVITY_CALCULATED_FROM_REVIEW_NOT_PUBLISHED_END_DATE; EXACT_FINAL_ANDA_NOT_SEPARATELY_RECHECKED;NO_DISQUALIFICATION_FROM_INDIRECT_BIOSIMILAR. Final operational judgment adopted; no verified=1 promotion. Update when evidence is found.Source
Independent legal-event information

Litigation & Settlement History

Settlement launch rights generally apply only to the named parties and product scope. These records do not change GenericRadar patent/exclusivity anchors or current decisions.

No litigation or settlement record currently linked to this product.